OncoMatch/Clinical Trials/NCT04615143
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
Is NCT04615143 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Tislelizumab and Tislelizumab combined with Levatinib for recurrent hepatocellular carcinoma.
Treatment: Tislelizumab · Tislelizumab combined with Levatinib — This non-randomized phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab or Tislelizumab combined with Lenvatinib as neoadjuvant treatment for resectable RHCC patients
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: curative ablation
Diagnosed as recurrent hepatocellular carcinoma after curative treatment
Cannot have received: transarterial chemoembolization
Previously received any transarterial chemoembolization
Cannot have received: immunotherapy
Previously received any...immune therapy
Cannot have received: other local or systemic liver cancer treatments
Exception: except for curative ablation
Previously received any...other local or systemic liver cancer treatments, except for curative ablation
Lab requirements
Liver function
child-pugh score 5-7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04615143 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior transarterial chemoembolization, immunotherapy, other local or systemic liver cancer treatments disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages